Earnings summaries and quarterly performance for MIMEDX GROUP.
Executive leadership at MIMEDX GROUP.
Joseph H. Capper
Detailed
Chief Executive Officer
CEO
DR
Doug Rice
Detailed
Chief Financial Officer
KM
Kimberly Maersk-Moller
Detailed
Chief Commercial Officer
RS
Ricci S. Whitlow
Detailed
Executive Vice President and Chief Operating Officer
WF
William F. Hulse IV
Detailed
General Counsel and Chief Administrative Officer
Board of directors at MIMEDX GROUP.
Research analysts who have asked questions during MIMEDX GROUP earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
6 questions for MDXG
Also covers: AVDL, BFLY, BVS +17 more
Bradley Bowers
Mizuho Securities USA LLC
4 questions for MDXG
Also covers: COO, TEM, TFX
CB
Carl Byrnes
Northland Capital Markets
4 questions for MDXG
Also covers: ALVO, BLFS, BWAY +6 more
RO
Ross Osborn
Cantor Fitzgerald
4 questions for MDXG
Also covers: AXGN, CERS, CVRX +12 more
AP
Anthony Petrone
Mizuho Group
2 questions for MDXG
Also covers: ADMA, ALC, AXGN +24 more
BO
Brooks O'Neil
Lake Street Capital Markets
2 questions for MDXG
Also covers: ARAY, ATEC, BBNX +11 more
DT
David Turcotte
CJS Securities
2 questions for MDXG
Frank Takkinen
Lake Street Capital Markets
2 questions for MDXG
Also covers: ANGO, AORT, AXGN +18 more
Recent press releases and 8-K filings for MDXG.
MiMedx Group Reports Record 2025 Results, Authorizes Share Buyback, and Provides 2026 Guidance
MDXG
Earnings
Guidance Update
Share Buyback
- MiMedx Group achieved record full-year 2025 net sales of $419 million and adjusted EBITDA of nearly $106 million, ending the year with a net cash balance of $148 million.
- In Q4 2025, net sales increased 27% year-over-year to $118 million, with both wound and surgical businesses growing at or above 25%, contributing to an adjusted EBITDA of $29 million, or 25% of net sales.
- The company authorized a share repurchase program of up to $100 million over the next two years, aiming to deploy capital opportunistically given its strong cash balance and belief that its stock is undervalued.
- For full-year 2026, MiMedx expects revenue in the range of $340 million-$360 million and adjusted EBITDA in the mid to high teens, anticipating near-term disruption in the wound care market due to new reimbursement frameworks while projecting continued strong growth in its surgical business.
3 days ago
MDXG Reports Record FY 2025 Results and Authorizes Share Repurchase Amidst Wound Care Market Changes
MDXG
Earnings
Share Buyback
Revenue Acceleration/Inflection
- MiMedx Group achieved record full-year 2025 net sales of $419 million, a 20% increase over 2024, and adjusted EBITDA of nearly $106 million, representing an adjusted EBITDA margin of over 25%.
- In Q4 2025, net sales reached a record $118 million, growing 27% year-over-year, with both wound and surgical businesses contributing significantly. The company concluded the year with a net cash balance of $148 million.
- The wound care market faces disruption from new Medicare reimbursement rates for skin substitutes, effective January 1, 2026, which is anticipated to result in lower gross margins in 2026.
- The surgical business demonstrated strong growth, up 20% for the full year 2025 and 25% in Q4, driven by investments and new product introductions such as AMNIOFIX Thyroid Shield. This momentum is expected to persist into 2026.
- The board authorized a share repurchase program, allowing for the deployment of up to $100 million to buy back stock over the next two years.
3 days ago
MiMedx Group Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance, and Authorizes Share Repurchase
MDXG
Earnings
Guidance Update
Share Buyback
- MiMedx Group achieved strong financial results for Q4 2025, with net sales of $118 million, representing 27% year-over-year growth, and adjusted EBITDA of $29 million, or 25% of net sales. For the full year 2025, net sales reached $419 million, a 20% increase over 2024, and adjusted EBITDA was nearly $106 million.
- The company ended 2025 with a net cash balance of $148 million and announced that its board authorized a share repurchase program of up to $100 million over the next two years.
- For full-year 2026, MiMedx Group provided revenue guidance in the range of $340 million to $360 million and expects adjusted EBITDA to be in the mid to high teens as a percentage of net sales. Revenue is anticipated to be lowest in Q1, with substantial increases in subsequent quarters.
- The wound care market is experiencing disruption due to new Medicare reimbursement rates effective January 1st, 2026, while the surgical business demonstrated robust growth of 20% for the full year 2025, with continued momentum expected.
3 days ago
MiMedx Reports Record Q4 and Full-Year 2025 Results, Issues 2026 Guidance
MDXG
Earnings
Guidance Update
Share Buyback
- MiMedx reported record fourth-quarter and full-year 2025 results, with Q4 net sales of $118 million and full-year adjusted EBITDA of nearly $106 million, ending the year with a net cash position of about $148 million.
- Profitability was strong in Q4 2025, with a GAAP gross margin of 84% and adjusted EBITDA of $29 million (25% of sales), resulting in GAAP net income of $15 million (EPS $0.14).
- Management warned of market disruption in the wound-care market due to Medicare reimbursement changes, including a $127/cc price cap, designating 2026 as a transition year.
- The company provided 2026 guidance of $340–360 million in revenue and mid- to high-teens adjusted-EBITDA margins.
- MiMedx authorized up to $100 million in share repurchases.
3 days ago
MIMEDX Announces Record Q4 and Full Year 2025 Results, Provides 2026 Outlook, and Authorizes Share Repurchase Program
MDXG
Earnings
Guidance Update
Share Buyback
- MIMEDX reported record fourth quarter and full year 2025 operating and financial results, with net sales growing 27% year-over-year for Q4 2025 to $118.095 million and 20% for the full year to $418.630 million.
- For Q4 2025, the company achieved GAAP net income of $15.191 million and diluted earnings per share of $0.10, with Adjusted EBITDA of $29.375 million, representing 24.9% of net sales.
- The company estimates 2026 net sales to be in a range of $340 million to $360 million and projects Adjusted EBITDA margin to be in the mid-to-high teens.
- MIMEDX also authorized a $100 million share repurchase program.
- The company anticipates that short-term disruptions caused by Medicare reimbursement changes in the Wound market will likely impact 2026 revenue.
3 days ago
MIMEDX GROUP, INC. Updates Investor Presentation with Q3 2025 LTM Financials and 2026 Outlook
MDXG
Earnings
Guidance Update
Product Launch
- MIMEDX GROUP, INC. reported LTM Net Sales of $393 million, LTM Adjusted EBITDA of $96 million (representing 24% of net sales), and a Net Cash Balance of $124 million as of Q3 2025, which is a 77% increase compared to Q3 2024.
- The company is strategically focused on expanding its presence in the Wound and Surgical markets, achieving 26% surgical growth in Q3, driven by products such as AMNIOFIX and AMNIOEFFECT, and plans to launch new products like EPIXPRESS and CHORIOFIX.
- MIMEDX anticipates that CMS reform in 2026 will significantly impact the wound care landscape, leading to a meaningful reduction in Medicare spend and a projected shift of patient volume from mobile and home-based care settings back to hospital outpatient and Wound Care Centers.
Jan 12, 2026, 1:04 PM
MIMEDX Secures Exclusive U.S. Distribution for RegenKit®-Wound Gel
MDXG
Product Launch
New Projects/Investments
- MiMedx Group, Inc. has secured an exclusive agreement with Regen Lab USA LLC for the U.S. distribution of RegenKit®-Wound Gel.
- RegenKit®-Wound Gel is an FDA-approved (2022) autologous platelet-rich plasma and thrombin serum wound gel, nationally covered by CMS and LCD for chronic wounds under HCPCS code G0465.
- This addition expands MIMEDX's Advanced Wound Care portfolio with a differentiated autologous solution, strengthening its competitive position ahead of January 1, 2026, LCD implementation.
Dec 22, 2025, 2:43 PM
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
MDXG
New Projects/Investments
- MiMedx Group, Inc. (MIMEDX) commented on the Centers for Medicare and Medicaid Services (CMS) CY 2026 Physician Fee Schedule (PFS) final rule, which was published on Friday.
- MIMEDX believes the new PFS will help reduce fraud, waste, and abuse in the skin substitute industry, leading to increased market stability and predictability.
- CEO Joseph H. Capper stated that the final rule, which aligns with the July proposal, presents a significant opportunity for MIMEDX due to its competitive advantages, including efficient operations, a strong commercial organization, best-in-class technology, a robust IP portfolio, and an excellent balance sheet.
- The company plans to leverage its strengths to gain market share as the market adapts to the new reimbursement environment and will continue to advocate for further improvements.
Nov 3, 2025, 2:15 PM
MiMedx Reports Record Q3 2025 Results and Raises Full-Year Guidance
MDXG
Earnings
Guidance Update
Product Launch
- MiMedx achieved record Q3 2025 revenue of $114 million, marking 35% year-over-year net sales growth, and reported adjusted EBITDA of $35 million, or 31% of net sales.
- The company has raised its full-year 2025 revenue growth guidance to mid to high teens and expects adjusted EBITDA margin to be at least in the mid-20% range.
- Net cash increased by $23 million in Q3 to $124 million, with projections to end 2025 with a net cash balance exceeding $150 million.
- The surgical business demonstrated 26% growth in Q3 2025, while the wound franchise grew 40%.
- MiMedx is preparing for Medicare reimbursement reforms, anticipated to be implemented in early 2026, which include a proposed fixed payment of $125.38 per square centimeter for skin substitutes, and expects to outperform the market following these changes.
Oct 29, 2025, 8:30 PM
MiMedx Group, Inc. Reports Record Q3 2025 Financial Results and Raises Full-Year Outlook
MDXG
Earnings
Guidance Update
Revenue Acceleration/Inflection
- MiMedx Group, Inc. reported record net sales of $114 million for the third quarter of 2025, representing a 35% increase year-over-year. This growth was primarily driven by a 40% increase in Wound product sales and a 26% increase in Surgical product sales.
- For the third quarter of 2025, the company achieved GAAP net income of $17 million and diluted earnings per share of $0.11.
- Adjusted EBITDA for Q3 2025 was $35 million, or 31% of net sales.
- As of September 30, 2025, MiMedx Group, Inc. had $142 million in cash and cash equivalents, with a net cash position of $124 million after debt.
- The company raised its 2025 financial outlook, now expecting net sales growth in the mid-to-high teens and an Adjusted EBITDA margin of at least mid-20% for the full year.
Oct 29, 2025, 8:07 PM
Quarterly earnings call transcripts for MIMEDX GROUP.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more